Add to Calendar 8/26/2020 8:00:00 AM 8/27/2020 5:00:00 PM 2020 State of Possible Conference

Special thanks to our Platinum Sponsor Morgan Stanley

Registered attendees will receive an email with the subject line “Welcome to the State of Possible Conference 2020 - Event Access Link” from registrations@bizzabo.com.


The State of Possible Conference, MassBio's Annual Meeting, will now be hosted virtually on August 26-27, 2020. Featuring interactive networking and a groundbreaking viewer experience, this event will not be your average webinar.  

We will celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks®, inspiring and engaging content in the style of a TED Talk.

"It's the Woodstock of Life Sciences, with all-star performers playing their greatest hits all on one stage.” – 2019 State of Possible Conference attendee
 
If you haven’t attended our State of Possible Conference before, it is the premier east coast life sciences conference. We have some of the brightest names in biotech talking about the issues impacting our industry, covering topics from the realities of precision medicine to advancing new drug targets faster.

To inquire about sponsorship opportunities, contact Laura Rudberg.

2020 State of Possible Conference Refund Policy

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
 Online Conference, Link will be sent in advance of the event.
Managing Director, Deloitte
Mathias Cousin is a Senior Manager at the Boston office of Monitor Deloitte. Mathias co-leads the pre-commercial life sciences practice in New England and has deep experience in helping biotech clients explore and define growth options, and scale their organizations. He spends a significant part of his practice working with cell and gene therapy companies, across autologous and allogeneic platforms. Prior to joining Monitor, he worked in oil & gas and at a biotech startup in Paris where he helped lead business development and raise the series A. He studied business and economics at ESCP-EUROPE & Paris Dauphine University. In his free time, he enjoys spending time biking and with his wife and two young but fast growing kids.

Brought to you by